Navamedic ASA · OSL:NAVA
Navamedic ASA — Q1 2022 Earnings Presentation
27 slides from Navamedic ASA's earnings presentation, May 10, 2022
Slide 1: First quarter results 2022
Q1 2022 First quarter results 2022 Navamedic ASA 10 May 2022 Kathrine Gamborg Andreassen, CEO Lars Hjarrand, CFO 1
Slide 2: Highlights
Highlights Highlights Strong underlying demand and solid quarter despite temporary Strengthened footprint in obesity through acquisition of Impolin AB supply challenges in May 2022 Continued strong demand for Mysimba®, but reduced revenue due to the temporary out-of-stock situation Strong performanc
Slide 3: Navamedic in brief
Navamedic in brief Nordic pharma company targeting growth in Northern Europe A reliable supplier of high- Presence in all Nordic Strong local competence in Ambitious growth strategy, quality pharma products, countries, Baltics and regulatory, reimbursement, high-potential pipeline and delivered to h
Slide 4: Updated ambition of building a NOK 1 billion revenue company mid-term including M&A
Navamedic in brief MID-TERM AMBITION 20% annual organic growth with Updated ambition of building a NOK 1 billion revenue a mid-term ambition of building a NOK 1 billion company with a company mid-term including M&A gross margin of at least 40% and an EBITDA margin of 15% Bolt-on acquisitions of prod
Slide 5: On track towards 20% Y/Y revenue growth target
On track towards 20% Y/Y revenue growth target Consistent positive trend in revenue and EBITDA • Strong revenue growth over time driven by strong market trends, successful build-up of new categories, M&A and +33% 300 000 30% distribution partnership 250 000 25% • Normal fluctuation in revenue growth
Slide 6: Key portfolio developments
Key portfolio developments Strong demand development across most products. MEDICAL CONSUMER BRANDED SPECIALTY NUTRITION HEALTH GENERICS PHARMA Q1 2022 revenue (YoY growth): 13.8 (13%) Q1 2022 revenue (YoY growth): 13.5 (18%) Q1 2022 revenue (YoY growth): 18.4 (28%) Q1 2022 revenue (YoY growth): 17.4
Slide 7: Obesity – a global disease with severe health risks
Key portfolio developments Obesity – a global disease with severe health risks 13% OF THE GLOBAL POPULATION World Health Organization (WHO) defines obesity as SUFFER FROM OBESITY abnormal or excessive fat accumulation that presents a Contributing risk factor for diseases such as cardiovascular risk
Slide 8: The Impolin acquisition | About Impolin and Modifast
The Impolin acquisition | About Impolin and Modifast Unique position in Sweden, great potential in the Nordics Impolin in short: • Unique position in Sweden with strong products and sales channels • Solid growth and profitability profile • Revenue 2021: SEK 52 million (+9.2% Y/Y) • 2021 EBIT margin:
Slide 9: The Impolin acquisition | Strategic rationale
The Impolin acquisition | Strategic rationale Strengthens and complements Navamedic’s position within obesity in the Nordics • Impolin’s strong position in Sweden With Impolin’ product Modifast and MedMade, Navamedic supports weight will be further boosted by loss across the whole user journey Navam
Slide 10: Specialty Pharma
Specialty Pharma Strong market development, but delivery issues due to change in regulatory approval process CONTINUED STRONG • Out-of stock situation for WHOLESALE Mysimba® in the second DEVELOPMENT Q1 2022 REVENUE half Q1 due to change in 17.4 MNOK 89% increase from Q1 2021 – Norway regulatory app
Slide 11: Medical Nutrition
Medical Nutrition Solid development for PKU and Ketogen products Q1 2022 REVENUE GROWTH DRIVERS 13.8 MNOK (Q1 2021: 12.2 MNOK) • Continued good growth for the key product area PKU products • Strong development for Ketogen products IEM Products for treatment of Inborn Errors of Metabolism (IEM), a li
Slide 12: Consumer Health
Consumer Health Successfully developing gastro category Q1 2022 REVENUE 13.5 MNOK GROWTH DRIVERS • IBS product Alflorex® and (Q1 2021: 11.4 MNOK) GeloRevoice® throat lozenges with solid growth during the quarter • Successful launch of new gastro product ranges SmectaGo® and Forlax ® 12
Slide 13: Branded Generics
Branded Generics Strong traction for antibiotics, with revenue visibility from successful tender wins Q1 2022 REVENUE 18.4 MNOK GROWTH DRIVERS (Q1 2021: 14.4 MNOK) • Strong performance for the antibiotic portfolio • New tenders won for Imdur® in The Netherlands from 2023 13
Slide 14: Financials
FINANCIALS @ Navamedic
Slide 15: Key consolidated profit and loss figures
Financials In Q1 2022, revenues grew by 7.4% compared to the same quarter last year Key consolidated profit and loss figures Gross Profit came in at 39.4% due to favorable product mix despite low (in NOK '1000) Q1 2022 Q1 2021 FY 2021 revenues of Mysimba Operating revenues 62 996 58 644 278 439 Gros
Slide 16: Assets
Financials Assets The change in Goodwill is due to currency (in NOK '1000) 31.03.2022 31.03.2021 31.12.2021 effect Goodwill 59 280 61 121 61 031 Deferred tax assets 9 168 9 168 9 168 Shares in associated companies is moved Other intangible assets 26 031 30 913 27 342 to financial assets as Observe M
Slide 17: Equity and liabilities
Financials Equity and liabilities (in NOK '1000) 31.03.2022 31.03.2021 31.12.2021 Equity ratio of 50.7%. Total equity 151 953 145 269 151 237 Non-current license liabilities 8 017 6 049 8 171 Loans and borrowings in total is Loans and borrowings 28 182 19 526 38 980 unchanged but a part has been mov
Slide 18: Cash flow Group – total operations
Financials Cash flow Group – total operations The cash flow from Operating (in NOK '1000) Q1 2022 Q1 2021 FY 2021 Activities is mainly the result of Net Net cash flow from operating activities -18 494 -12 435 -1 300 profit coupled with changes in net working capital and the main impact Net cash flow
Slide 19: Summary & Outlook
SUMMARY & OUTLOOK 19 @ Navamedic
Slide 20: Summary and outlook
Navamedic ASA Summary and outlook Delivering on our strategy: Building a leading Nordic pharma company targeting growth in Northern Europe Q1 highlights MID-TERM AMBITION • Continued to strengthen the core by driving underlying growth in the existing portfolio 20% annual organic • Strong growth in m
Slide 21: Q&A
Q&A @ Navamedic
Slide 22: Thank you for your attention!
Thank you for your attention! Navamedic’s Annual General Meeting 2022 will be held 2nd of June 2022 Navamedic’s Q2 2022 presentation will be on 12 of August 2022 th 22
Slide 23: Appendix
APPENDIX @ Navamedic
Slide 24: Condensed consolidated statement of comprehensive income
Navamedic ASA Condensed consolidated statement of comprehensive income (in NOK '1000) Q1 2022 Q1 2021 FY 2021 Operating revenues 62 996 58 644 278 439 Total revenue 62 996 58 644 278 439 Cost of materials -38 161 -35 432 -166 695 Gross profit 24 835 23 213 111 744 Gross profit % 39.4 % 39.6 % 40.1 %
Slide 25: Condensed consolidated statement of cash flows
Navamedic ASA Condensed consolidated statement of cash flows (in NOK '1000) Q1 2022 Q1 2021 FY 2021 Cash flow from operating activities Profit before tax 521 -3 292 2 358 Adjusted for: Depreciation, amortization and impairment 1 830 1 341 6 716 Financial income / expenses without cash effect -6 789
Slide 26: Basis for preparation and Alternative Performance Measures
Appendix Basis for preparation This presentation provides financial highlights for the quarter for Navamedic Group. The financial information is not reported according to the requirements in IAS 34 (Interim Financial Reporting) and the figures are not audited. The same measurement principles as pres
Slide 27: Copyright and disclaimer
Appendix Copyright and disclaimer Copyright Copyright of all published material including photographs, drawings and images in this document remains vested in Navamedic and third party contributors as appropriate. Accordingly, neither the whole nor any part of this document shall be reproduced in any